Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

invbiotech 15 posts  |  Last Activity: May 24, 2016 12:56 PM Member since: Feb 28, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Worth Watching Stocks Alert: Celldex Therapeutics, Inc. (NASDAQ:CLDX), 21Vianet Group Inc (NASDAQ:VNET)
    May 24, 2016 Rose Comeaux 0 Comment 21Vianet Group, Celldex Therapeutics, CLDX, NASDAQ:CLDX, NASDAQ:VNET, VNET
    On Tuesday, Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), added 5.96% and closed at $ 4.27 in the last trading session. The last trading range of the stock ranges between $ 4.03 and $ 4.50. Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. Its earlier stage drug candidates in clinical development comprise CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor.

    Sentiment: Strong Buy

  • Reply to

    +.35

    by martyboy0077 May 23, 2016 9:59 AM
    invbiotech invbiotech May 23, 2016 3:37 PM Flag

    CDX301/1401 abstract at ASCO looks v. promising & Glemba high prob will come through on pivotal trial in TNBC pts.

    Sentiment: Strong Buy

  • Reply to

    State Street making a bet on CLDX

    by paulsshaffer11 May 18, 2016 6:22 PM
    invbiotech invbiotech May 19, 2016 2:33 PM Flag

    Anyone have the more recent May IO data?

    Sentiment: Strong Buy

  • Reply to

    ASCO CDX 301/1401 Abstract

    by fludyspnea May 18, 2016 5:42 PM
    invbiotech invbiotech May 19, 2016 12:59 PM Flag

    If the CDX301+1401+poly group shows a relapse rate of less than 10% , then CLDX has a major advance in the treatment of high risk melanoma. Totally out of the blue, who would've thought?

    Sentiment: Strong Buy

  • Reply to

    VP/SVP Global Regulatory Affairs

    by btchinvstr May 9, 2016 3:17 PM
    invbiotech invbiotech May 10, 2016 3:36 PM Flag

    """The VP/SVP will identify the key strategic regulatory needs for early through late stage programs and post launch...""""

    "late stage" and "post launch"...there is only one therapeutic in the CLDX pipeline that is approaching this stage: Glemba. Open label pivotal trial for glemba, so perhaps CLDX is close to nailing this one down...

    Sentiment: Strong Buy

  • The Stemcetrx Ab drug conjugate in similar class as CLDX's glemba, and at least in pretreated patients doesn't appear more effective than Glemba:

    """April 28 (Reuters) - AbbVie Inc placed another bet on new cancer drugs on Thursday with a $5.8 billion deal, as it seeks new sources of revenue ahead of patent expirations on its flagship $14 billion-a-year Humira arthritis drug.

    Shares of AbbVie fell 7.3 percent immediately after it announced the deal but pared losses to trade down only 1.7 percent at $59.64 later on Thursday morning. The company lowered its 2016 earnings forecast due to the deal's expected dilutive impact this year and for several years to come.

    The suburban Chicago drugmaker said it would buy privately held Stemcentrx and its experimental lead treatment for small cell lung cancer, which accounts for about 10-15 percent of all lung cancers and is notoriously difficult to treat.

    Companies with innovative cancer drugs, especially ones that spur the immune system to attack tumors, are attractive takeover targets. These life-extending new treatments can command extremely high prices that health insurers seem willing to pay for, unlike some other therapeutic categories where they are putting pressure on price.


    Abbott Labs to spend $19.3 billion to buy St. Jude Medical AP 23 mins ago
    AbbVie forges deeper into cancer, as clock ticks for Humira Reuters 2 hrs 2 mins ago
    More
    Also on Thursday, French drugmaker Sanofi went public with its $9.3 billion offer to buy Medivation, which makes prostate cancer treatment Xtandi.

    Stemcentrx's drug, called Rova-T, is a toxic chemical that has been loaded onto an antibody. It targets a protein called DLL3 that is found in more than 80 percent of patients with the cancer. A biomarker is used to help select patients whose cancers express the protein.""""

    Sentiment: Strong Buy

  • invbiotech invbiotech Apr 13, 2016 7:11 PM Flag

    Can you read and comprehend the following combo trial of Varli and Nivo, (from ClinicalTrials.gov)? Do you understand the implications of this CLDX trial, and how it relates to the CD27 + anti-PD1 report, and why a billionaire like Parker is investing in this field?

    "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
    This study is currently recruiting participants. (see Contacts and Locations)
    Verified January 2016 by Celldex Therapeutics
    Sponsor:
    Celldex Therapeutics
    Collaborator:
    Bristol-Myers Squibb
    Information provided by (Responsible Party):
    Celldex Therapeutics
    ClinicalTrials.gov Identifier:
    NCT02335918
    First received: December 18, 2014
    Last updated: January 20, 2016
    Last verified: January 2016
    History of Changes
    Full Text View Tabular ViewNo Study Results PostedDisclaimerHow to Read a Study Record
    Purpose
    This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as BMS-936558). Both drugs target the immune system and may act to promote anti-cancer effects. The study will enroll patients with the following cancer types: Non-Small Cell Lung Cancer, Melanoma, Colorectal, Ovarian or Head and Neck Squamous Cell Carcinoma."

    Sentiment: Strong Buy

  • invbiotech invbiotech Apr 13, 2016 1:26 PM Flag

    Don't know what meds you are on "lucky", but they have turned your brain into total mush. Actually this is a very interesting IO report. And right on the money, with news announced this morning, which I post here because I doubt you read the news. And I capitalize the important point for benefit of your second grade reading comprehension.

    +++WASHINGTON — CANCER IMMUNOTHERAPY will get a hefty dose of its own moonshot Wednesday when a tech billionaire announces he's giving $250 million to six cancer centers nationwide, including Manhattan's Memorial Sloan Kettering and Stanford.

    Sean Parker, founder of the music file-sharing service Napster and the founding president of Facebook, says he is putting his MONEY behind CANCER IMMUNE THERAPY because it is at a turning point and would benefit from research that is done without regard for the costs.

    IMMUNOTHERAPY, which enhances the body's immune system to kill cancer cells, is best known these days because former president Jimmy Carter was on an IMMUNE-BASED DRUG treatment when he announced in December that there is NO DETECTABLE CANCER in his body.

    Parker's ENORMOUS CASH INFUSION is the largest ever for CANCER IMMUNOTHERAPY — and one of the largest ever for cancer research — and comes three months after President Obama called for a $1 billion federal cancer research program that he dubbed a “moonshot." The estate of the billionaire shipping magnate Daniel Ludwig donated $540 million to six cancer centers in 2014 and Nike co-founder Phil Knight pledged $500 million to cancer researchers at Oregon Health & Science University in 2013.+++

    Sentiment: Strong Buy

  • ACAD and CLDX have been trading pretty closely, including comparable short positions. Will be interesting to see effect on CLDX.

    Sentiment: Strong Buy

  • March 23, 2016 2:32 PM EDT Send to a Friend
    Paris-based Sanofi (NYSE: SNY) is interested in acquiring Medivation (Nasdaq: MDVN), a U.S.-listed biopharmaceutical company.......

    Sentiment: Strong Buy

  • invbiotech invbiotech Mar 11, 2016 3:25 PM Flag

    CLDX's partner BMY has approved going into PII trials with Varli+Opdivo combo in half a dozen cancer indications. Check ClinicalTrials.gov for latest info on these trials.

    Sentiment: Strong Buy

  • Reply to

    Some thoughts on Rindo.

    by rinostarr14 Mar 2, 2016 3:16 PM
    invbiotech invbiotech Mar 2, 2016 4:32 PM Flag

    Thx for your post, rino.

    """I was never part of the rindo clinical trial, but my alma mater is involved in the study"""

    What kind of responses did the oncologists see with rindo at your hospital- I assume you checked with your colleagues?

    Sentiment: Strong Buy

  • The tide is turning. Rintega, Glemba and Varli will put CLDX valuation into KITE and JUNO territory, perhaps even beyond as the value of the CLDX pipeline becomes evident!

    Sentiment: Strong Buy

  • invbiotech invbiotech Mar 2, 2016 2:04 PM Flag

    Dr. Howard Liang when he projected $8 Billion/yr revenue for Varli in '13:

    Leerink Swann maintained an Outperform rating on Celldex Therapeutics (NASDAQ: CLDX) and raised its price target to $45.00 (from $28.00). Analyst Howard Liang discussed views on CDX-1127 as an immunotherapy play.

    "Ahead of first clinical data on CDX-1127 expected at the Society for Immunotherapy of Cancer (SITC) meeting (Nov. 7-10, National Harbor, MD), we spoke with several MEDACorp key opinion leaders (KOLs) and closely examined available data. Our work enhances our conviction that the potential of immuno-oncology (IO) agents could go far beyond the already impressive data shown so far for PD-1 immune checkpoint inhibitors, and we see an analogy to the HCV space in that the winner may lie in the best combination instead of the best anti-PD1 compound," said Liang.

    "Our checks addressed several questions on CDX-1127, which we believe is highly interesting as a co-stimulatory agonist. As a combination partner for immune checkpoint inhibitors such as anti-PD-1 agents, we believe the efficacy bar is not high based on our analysis of early clinical data on other IO agents, and we believe any demonstration of single-agent activity coupled with a clean safety profile could position CDX-1127 as one of the leading candidates for PD-1 combination," he added.

    Sentiment: Strong Buy

  • Reply to

    Published today

    by cldxlong Mar 1, 2016 2:35 PM
    invbiotech invbiotech Mar 1, 2016 4:47 PM Flag

    Rintega should've been on the market a long time ago. What more does the FDA want?

    Sentiment: Strong Buy

CLDX
4.22+0.01(+0.24%)May 25 4:00 PMEDT